Variety of Issues Undermine Efficacy Data As FDA Takes Benlysta To Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies focused on lupus patients with less severe disease, throwing into question the drug's efficacy in patients with higher risk of mortality.
You may also be interested in...
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
Assuming the lupus drug gets FDA approval, HGSI and its 50-50 partner GlaxoSmithKline are ready to launch Benlysta by the end of the first quarter.